Using IL-2, adenoviral gene therapy in prostate cancer patiets was welltolerated; inducing tumor lymphocytic infiltration, increase in IFNγ and IL-4secretion within the tumor, and decrease in prostate specific antigen (PSA)levels (Trudel et al., 2003). This evidence concerns the gene KLK3 and prostate carcinoma.